to page content
to site navigation
The Resource Center has all the info you'll need From content to user feedback, the resource center has the information you need for every level of the entrepreneurial process.
What's the best strategy for developing and launching a new medical device? The uncertainty of the regulatory and reimbursement environment in the United States has made venture capitalists wary of investing in new medical device companies, but that doesn't mean all is lost.
In the healthcare business landscape, there's plenty of healthcare investing happening. However, there are still medical problems that could benefit from more investment. Read more about them.
The number of life sciences venture deals was down in the third quarter and first-time funding was down as well. Read more about the reasons behind the numbers.
Venture firms are approaching angel investor groups to co-invest at the growth stage of startups. Read more about the impact this could have on startup health IT companies.
Medical foundations play a role in helping medicine advance through their philanthropy, but sometimes even the most well-intentioned of them can lose their way. Read more about how these foundations can stay focused on their goals.
Many would agree that surgeons are qualified to create innovative medical devices that may be superior to what is currently available. But the controversy arises when surgeons begin to profit by purchasing their own products for use in their patients.
In a venture funding climate seeking large returns, thousands of potentially successful entrepreneurial startups can't get the financing they need to make a difference in the economy and in the culture. The problem isn't a new one, but it is a damaging one.
The number of healthcare venture deals is at its lowest level in at least five quarters, according to a new report. However, healthcare seed investment hit a record high in the same quarter.
There's stability and then there's outright growth. For healthcare business owners looking for angel funding, they'll have to accept the former and wait some more on the latter. But at least it's progress.
Regenerative medicine has come a long way in recent years, leading some venture capitalists to consider investing in it. The roadblock to investing in this field is not a lack of funds, but rather a lack of a clear explanation of regenerative medicine's commercial applications, says one former venture capitalist.
Want to get connected? Sign up to receive regular news, polls and updates from The Kauffman Foundation.